Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Payables (2016 - 2026)

Insight Molecular Diagnostics' Payables history spans 7 years, with the latest figure at $2.5 million for Q4 2025.

  • On a quarterly basis, Payables rose 508.61% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 million, a 508.61% increase, with the full-year FY2025 number at $2.5 million, up 508.61% from a year prior.
  • Payables hit $2.5 million in Q4 2025 for Insight Molecular Diagnostics, up from $1.1 million in the prior quarter.
  • Over the last five years, Payables for IMDX hit a ceiling of $3.3 million in Q1 2022 and a floor of $379000.0 in Q2 2024.
  • Historically, Payables has averaged $1.4 million across 5 years, with a median of $1.2 million in 2021.
  • Biggest five-year swings in Payables: tumbled 82.74% in 2024 and later skyrocketed 508.61% in 2025.
  • Tracing IMDX's Payables over 5 years: stood at $1.8 million in 2021, then plummeted by 30.77% to $1.3 million in 2022, then crashed by 63.93% to $452000.0 in 2023, then decreased by 7.52% to $418000.0 in 2024, then skyrocketed by 508.61% to $2.5 million in 2025.
  • Business Quant data shows Payables for IMDX at $2.5 million in Q4 2025, $1.1 million in Q3 2025, and $1.3 million in Q2 2025.